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Abstract
Background: Ursolic acid (UA), a pentacyclic triterpenoid carboxylic acid, is the major component of many plants including
apples, basil, cranberries, peppermint, rosemary, oregano and prunes and has been reported to possess antioxidant and
anti-tumor properties. These properties of UA have been attributed to its ability to suppress NF-kB (nuclear factor kappa B)
activation. Since NF-kB, in co-ordination with NF-AT (nuclear factor of activated T cells) and AP-1(activator protein-1), is
known to regulate inflammatory genes, we hypothesized that UA might exhibit potent anti-inflammatory effects.
Methodology/Principal Findings: The anti-inflammatory effects of UA were assessed in activated T cells, B cells and
macrophages. Effects of UA on ERK, JNK, NF-kB, AP-1 and NF-AT were studied to elucidate its mechanism of action. In vivo
efficacy of UA was studied using mouse model of graft-versus-host disease. UA inhibited activation, proliferation and
cytokine secretion in T cells, B cells and macrophages. UA inhibited mitogen-induced up-regulation of activation markers
and co-stimulatory molecules in T and B cells. It inhibited mitogen-induced phosphorylation of ERK and JNK and suppressed
the activation of immunoregulatory transcription factors NF-kB, NF-AT and AP-1 in lymphocytes. Treatment of cells with UA
prior to allogenic transplantation significantly delayed induction of acute graft-versus-host disease in mice and also
significantly reduced the serum levels of pro-inflammatory cytokines IL-6 and IFN-c. UA treatment inhibited T cell activation
even when added post-mitogenic stimulation demonstrating its therapeutic utility as an anti-inflammatory agent.
Conclusions/Significance: The present study describes the detailed mechanism of anti-inflammatory activity of UA. Further,
UA may find application in the treatment of inflammatory disorders.
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Introduction
Inflammation involves the activation and recruitment of
phagocytes (macrophages, neutrophils), NK cells, complement
system and secretion of cytokines like IL-1b, IL-6, TNF-a by
activated cells which are essential for the host defence system. The
chronic inflammation that persists even after elimination of
pathogen(s) has been associated with several diseases such as
cancer [1,2], neoplasms, inflammatory bowel disease, ulcerative
colitis [3,4], atherosclerosis, rheumatoid arthritis [5], asthma and
Alzheimer’s disease [6]. The damaging responses resulting from
chronic inflammation can be controlled by altering the molecular
mediators of an inflammatory response. The key targets are
proinflammatory cytokines and cytokine receptors (tumor necrosis
factor (TNF-a) and TNF-RII, IL-12, IL-6, interferon-c), enzymes
(COX-2, inosine monophosphate dehydrogenase), cell surface
molecules required for intercellular interactions and leukocyte
activation. Dysregulation of these cytokines and enzymes may
contribute to the pathogenesis of many chronic inflammatory
diseases [7,8]. Transcription factors (NF-kB, NF-AT and AP1)
along with mitogen-activated protein kinases (ERK, JNK, and
p38) are known to regulate these inflammatory cytokines and
enzymes and are being targeted by several investigators to
ameliorate chronic inflammation [9,10,11,12,13,14,15]. There
are several reports showing the involvement of reactive oxygen
species (ROS) and glutathione (GSH) in modulating these
immunologically important kinases and transcription factors and
resulting in altered immune responses [16,17]. The treatment
approaches for these inflammatory disorders are addressed by
administration of steroids and non-steroidal anti-inflammatory
drugs (NSAID) like azathioprine. All of these drugs are
accompanied by an array of side effects [18,19,20,21] restricting
their continuous usage and complicating treatment modalities.
Thus there is a need to identify safe and non-toxic anti-
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treatment of inflammatory disorders.
Ursolic acid, (UA; 3b-hydroxy-12-urs-12-en-28-oic acid), a
natural pentacyclic triterpenoid carboxylic acid is present in a
wide variety of plants, including apples, basil, bilberries,
cranberries, peppermint, rosemary, oregano [22]. Several bio-
chemical and pharmacological effects of UA such as anti-
inflammatory, antioxidant, anti-proliferative, anti-cancer, anti-
mutagenic, anti-atherosclerotic, anti-hypertensive, anti-leukemic
and antiviral properties are reported in a number of experimental
systems [23,24]. UA exhibited anti-inflammatory effects in
RAW264.7 cells (Mouse monocyte macrophage cell line) by
attenuating inducible nitric oxide synthase and cycloxygenase-2
expression [25,26]. The anti-proliferative, anti-tumor and anti-
leukemic properties have been shown to be mediated via
suppression of NF-kB activation and inhibiting the expression of
NF-kB regulated genes like lipoxygenase, COX-2, MMP-9, and
iNOS [27,28,29,30].
It is well known that activation of NF-kB, MAPKs, AP-1 and
NF-AT following major histocompatible complex-T cell receptor
(MHC-TCR) interaction is vital for the antigen induced
lymphocyte proliferation, cytokine secretion and survival [31]. In
resting T cells, NF-kB is sequestered into an inactive state by the
cytoplasmic inhibitor of NF-kB( I kBa). T cell activation through
TCR leads to the rapid activation of the IkB kinases (IKKs) via
protein kinase C and results in phosphorylation and subsequent
degradation of IkB proteins which allows nuclear translocation of
NF-kB [32]. Since dysregulation of NF-kB function is associated
with inflammation, any molecule that interferes with NF-kB
activation is a potential candidate for therapeutic strategy in the
treatment of inflammatory diseases. The present study was aimed
to investigate anti-inflammatory properties of UA in murine
lymphocytes. The molecular mechanism of action of UA for the
observed anti-inflammatory activity was also studied.
Results
UA inhibited Con A and anti-CD3/CD28 mAb induced
proliferation of lymphocytes in vitro
The potential immunomodulatory effects of UA were studied by
stimulating murine splenic lymphocytes with polyclonal T cell
mitogen Con A or with plate bound anti-CD3 plus soluble anti-
CD28 mAb in the presence or absence of UA. Lymphocyte
proliferation induced by Con A or anti-CD3/CD28 mAb was
assessed by CFSE dye dilution using a flowcytometer. As shown in
figure 1A–D, UA inhibited Con A induced lymphocyte prolifer-
ation in a dose dependent manner in vitro. UA at 5 mM
completely inhibited both Con A and anti-CD3/CD28 mAb
induced lymphocyte proliferation (Fig. 1B & D). This inhibition of
proliferation may be due to inhibition of entry of cells into S phase
of the cell cycle as evinced from cell cycle analysis (Fig. 1E). The
fraction of cells in S+G2/M phase of cell cycle in UA treated
lymphocytes stimulated with Con A was significantly lower than
that in lymphocytes stimulated with Con A alone (Fig. 1E). There
was a concomitant increase in the percentage of cells in G1 phase
of cell cycle in UA treated lymphocytes stimulated with Con A
than that in lymphocytes stimulated with Con A alone indicating
that UA induced G1 phase arrest in activated T cells (Fig. 1E).
This inhibition of mitogen and anti-CD3/CD28 mAb induced T
cell proliferation was not due to induction of cell death as this
inhibitory concentration of UA was found to be non-toxic to
lymphocytes when assessed by propidium iodide (PI) staining
(Fig. 1F&G).
UA inhibited proliferation of CD4+ T cells, CD8+ T cells
and B cells
T cells (CD4+ and CD8+) and B cells are the two major cell
types involved in the adaptive immune response following
pathogenic invasion. We studied whether UA acts on both these
cell types or is specific to a particular lineage of lymphocytes. As
shown in Fig. 2A–F, UA inhibited anti-CD3/CD28 mAb induced
proliferation of CD4+ T cells (Fig. 2A&B), CD8+ T cells
(Fig. 2C&D) and LPS stimulated proliferation of B cells
(Fig. 2E&F).
UA inhibited Con A, anti-CD3/CD28 mAb and LPS
induced cytokine secretion by lymphocytes, CD4+ T cells
and macrophages in vitro
Fig. 3 shows the secretion of IL-2, IL-4, IL-6 and IFN-c
cytokines by lymphocytes stimulated with Con A or anti-CD3/
CD28 mAb in the presence or absence of UA. Lymphocytes
stimulated with Con A or anti-CD3/CD28 mAb produced
significantly higher levels of IL-2, IL-4, IL-6 and IFN-c cytokines
(Fig. 3A & B). Treatment of cells with UA (5 mM) completely
inhibited both Con A and anti-CD3/CD28 mAb induced
secretion of IL-2, IL-4, IL-6 and IFN-c cytokines (Fig. 3A & B).
These results were in agreement with the earlier results showing
complete inhibition of Con A and anti-CD3/CD28 mAb induced
proliferation of lymphocytes by UA at 5 mM (Fig. 1B&D). Similar
anti-inflammatory effects of UA were observed on CD4+ T cells
when they were stimulated with anti-CD3/CD28 mAb in the
presence of UA. Treatment of purified CD4+ T cells with UA
prior to stimulation with anti-CD3/CD28 mAb led to complete
the inhibition of secretion of IL-2, IL-4, IL-6 and IFN-c (Fig. 3C).
It was also observed that treatment of splenic adherent
macrophages with UA prior to stimulation with LPS completely
inhibited the secretion of IL-6, IL-1b and TNF-a cytokine
(Fig. 3D).
Inhibition of gene expression in activated CD4+ T cells by
ursolic acid
Quantitative real time RT-PCR for 6 genes that are known to
be involved in T cell activation (IL-2), B cell activation
(phospholipase C gamma 2 (Plcg2)), cell division/cycle (cell
division cycle 25 homolog A (Cdc25a), E2F, growth arrest and
DNA damage 45 gamma (Gadd45g) and minichromosome
maintenance complex component 7 (Mcm7)) and functioning
(IFN-g) was carried out. On activation with CD3/CD28 mAb the
expression of all these genes was elevated in comparison to control
(Fig. 3E). But treatment of cells with UA prior to activation with
antiCD3/CD28 resulted in significant suppression of mRNA
levels of these genes except for Plcg2 (Fig. 3E).
UA inhibited up-regulation of activation markers and co-
stimulatory molecules on both T and B cells
Optimum T cell activation requires signaling through both T
cell receptor as well as through co-stimulatory proteins. Activation
of T cells only through TCR in the absence of a co-stimulatory
signals leads to T cell anergy. Also, T cell upon activation up-
regulate certain cell surface proteins which are necessary for
complete T cell activation and effector functions. The effect of UA
on T cell activation markers and co-stimulatory molecules was
studied to determine whether UA inhibits T cell activation and
induces T cell anergy. Fig. 4 shows the expression of early and late
T cell activation markers CD69 (Fig. 4A), CD25 (IL-2R-a, Fig. 4B)
and CD134 (Fig. 4C) and co-stimulatory molecule CD28 (Fig. 4D)
in lymphocytes treated with UA (5 mM, 4 h) and stimulated with
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higher expression of CD69, CD25, CD134 and CD28 as
compared to that in control cells (Fig. 4A–D). Treatment of
lymphocytes with UA prior to Con A stimulation completely
inhibited the Con A induced upregulation of CD69, CD134,
CD25 and CD28 expression on T cells (Fig. 4A–D). Interaction of
antigen bound MHC and CD80 (B7.1) and CD86 (B7.2) on
antigen presenting cells with TCR and CD28 on T cells
respectively provide the two signals required for complete T cell
activation. Lack of either MHC-TCR or CD28-CD80 interaction
impairs the immune response. We studied effects of UA on LPS
induced upregulation of CD19, CD80, CD86 and MHC II on
activated B cells. As shown in Fig. 4E-H, treatment of cells with
UA prior to LPS stimulation inhibited the upregulation of CD19,
CD80, CD86 and MHC II on activated leukocytes.
Modulation of intracellular redox status by UA
Intracellular ROS and GSH levels are known to pay an
important role in immune responses and several molecules have
been shown to exhibit their immunomodulatory activity via a
redox dependent manner [33]. Hence, we examined whether UA
also acts in a similar manner via modulation of cellular redox
status. Treatment of lymphocytes with UA significantly increased
the DCF (Dichlorodihydrofluorescein) (Fig. 5A) fluorescence at
5 mM. To ascertain whether the observed increase in intracellular
ROS is accompanied with a concomitant decrease in GSH levels
we checked the levels of intracellular GSH in lymphocytes
following UA treatment. We observed that 4 h after UA treatment
there was a significant decrease in the levels of GSH in
lymphocytes (Fig. 5B). To determine the role of redox in the
observed anti-inflammatory effects of UA we checked whether
antioxidants could abrogate the suppressive effects of UA. Fig. 5C–
E shows the effect of thiol and non thiol antioxidants on the
suppressive effect of UA on Con A induced proliferation and
cytokine secretion of lymphocytes. The suppression of Con A
induced lymphocyte proliferation and cytokine secretion by UA
could not be abrogated by thiol (glutathione (GSH), N-acetylcys-
teine (NAC) and dithiothreitol (DTT)) or non-thiol antioxidant
(trolox) suggesting that the effects of UA are independent of
cellular redox status (Fig. 5C–E).
UA suppressed mitogen induced MAPK, NF-kB, NF-AT
and AP-1 activation in lymphocytes
It is well known that following MHC-TCR engagement, a large
number of proteins including MAPkinases, NFkB, AP1 and NF-
AT are activated which co-ordinate with each other resulting in an
immune response. To study the molecular mechanism of action of
UA, we studied its ability to modulate signaling events that are
involved in T cell activation. Fig. 6, shows the effect of UA on Con
A induced MAPKinases (MEK, ERK and JNK), NF-kB, AP-1
and NF-AT activation in lymphocytes. Treatment of lymphocytes
with UA inhibited Con A induced ERK and JNK phosphoryla-
tion. The observed inhibition of ERK phosphorylation may be
due to the inhibition of mitogen induced phosphorylation of c-raf
and MEK which are upstream of ERK and are responsible for
ERK phosphorylation upon activation (Fig. 6A). Lymphocytes
treated with Con A (5 mg/ml) for 1 h showed degradation of IkB-
a in the cytosolic fraction and activation of NF-kB, NFAT and
AP-1 in the nuclear fraction as compared to that in vehicle treated
control cells (Fig. 6B–D). However, cells treated with UA (5 mM)
and then stimulated with Con A (5 mg/ml, 1 h) did not show IkB-
a degradation (Fig. 6B). UA suppressed Con A mediated
activation of all three important immunoregulatory transcription
factors NF-kB, NFAT and AP-1 (Fig. 6B–D). The addition of
excess unlabeled NF-kB (cold oligonucleotide, 100-fold) caused a
complete disappearance of the band, whereas mutated oligonu-
cleotide had no effect on DNA binding suggesting that the band
belongs to NF-kB(Fig. 6B). Fig. 6E&F shows the effect of UA on
Con A induced upregulation of NF-kB dependent genes in
lymphocytes. Stimulation of lymphocytes with Con A (5 mg/ml)
for 24 h resulted in significant upregulation of Bcl-2 and Bcl-xl
protein levels (Fig. 6E&F). This increase in the levels of NF-kB
dependent proteins (Bcl-2 and Bcl-xl) in Con A activated
lymphocytes was inhibited by treatment with UA (Fig. 6E&F).
UA delayed induction of graft-versus-host disease
To study the in vivo efficacy of UA, we studied its ability to
inhibit graft-versus-host disease (GVHD). Splenic lymphocytes
from C57BL/6 mice were incubated with UA in vitro (5 mM, 4 h)
and adoptively transferred to immunocompromised Balb/c mice.
The mice that received untreated control cells developed GVHD
that led to 100% death within 10 days (Fig. 7A) and demonstrated
typical symptoms of GVHD, including alopecia, scleroderma,
hunched posture, diarrhoea, and progressive weight loss. Howev-
er, in mice that received UA treated cells showed 30% survival in
better health for more than 30 days (Fig. 7A). Further, it was
observed that mice receiving UA treated lymphocytes experienced
inconspicuous weight loss as compared to control group (Fig. 7B).
Fig. 7C–E show that on day 3 and day 5 post allo-transplantation,
the levels of proinflammatory cytokines (IL-6, IFN-c and IL-2)
were significantly higher in the serum of mice receiving vehicle
treated allogenic lymphocytes as compared to those mice which
received UA treated allogenic lymphocytes. This observation
clearly shows potent anti-inflammatory activity of UA in vivo.
UA exhibited therapeutic potential by acting post-
mitogenic stimulation
To explore its therapeutic potential, UA was added to
lymphocytes post-mitogenic stimulation at different time points.
It was observed that UA was able to completely suppress Con A
Figure 1. Ursolic acid inhibits lymphocyte proliferation in vitro. (A) For cell proliferation analysis CFSE labelled lymphocytes were treated
with UA (0.25–5 mM, 4 h) and stimulated with the Con A (10 mg/ml) at 37uC for 72 h. Twenty thousand cells were acquired in a flowcytometer. Vehicle
treated cells served as control. Percent daughter cells were calculated from decrease in mean fluorescence intensity. (B) Each bar represents
percentage of daughter cells in each treatment group. (C & D) UA inhibits anti-CD3 induced T cell proliferation. CFSE labelled lymphocytes were
treated with UA (1 & 5 mM, 4 h) and stimulated with coated anti-CD3mAb (1 mg/ml) and soluble anti CD28mAb (1 mg/ml) at 37uC for 72 h. Percent
daughter cells were estimated by CFSE dye dilution. Representative histogram and corresponding bar diagram are shown in Fig. 1C and D
respectively. (E) UA inhibits Con A induced cell cycle progression: Lymphocytes were treated with UA (0.25–5 mM, 4 h) and stimulated with the Con A
(5 mg/ml) at 37uC for 72 h. The cells were stained with propidium iodide and twenty thousand cells were acquired in a flowcytometer. The hollow
bars represent percentage of cells containing less than 2n DNA (sub-G1/apoptotic cells), light gray bars show cells containing 2n DNA (in G1 phase)
and the dark gray bars indicate the cells containing more than 2n DNA (in S+G2/M phase). (F) Evaluation of the potential cytotoxicity of UA to
lymphocytes. Lymphocytes were cultured with UA (5 mM) for 24 h and cytotoxicity was measured by PI staining. Vehicle treated cells served as
control. Percentage apoptosis (pre-G1 peak) in lymphocytes was estimated and is shown in the histograms. (G) Each bar represents percentage of
apoptotic in each treatment group. Data points represent mean6S.E.M. from three replicates and three such experiments were carried out. *p,0.01,
as compared to vehicle treated cells and #p,0.01, as compared to Con A or antiCD3/CD28 stimulated cells.
doi:10.1371/journal.pone.0031318.g001
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was added up to 4 h after mitogenic stimulation (Fig. 7F).
Since UA inhibited the expression of co-stimulatory molecules
on activated T cells and B cells, we studied whether UA renders
these cells anergic and hence incapable to respond to any further
stimuli. We observed that splenic lymphocytes treated with UA for
4 h did not respond to mitogenic stimuli when activated with Con
A even though they were washed and rested for 48 h following UA
treatment. This shows that UA treated cells are hyporesponsive to
antigenic stimulation which might be due to a possible induction of
anergy (Fig. 7G).
Discussion
Triterpenoids form natural components of human diets. An
average of 250 mg per day of triterpenes, largely derived from
vegetable oils, cereals, fruits and vegetables is consumed [34].
Ursolic acid (UA) is a part of traditional medicine and has been
shown to possess many biological activities, such as antioxidative,
anti-inflammatory, anticancer and hepato-protective activities
[23]. Recent reports indicated that the anticarcinogenic, anti-
inflammatory, and proapoptotic effects of ursolic acid were due to
its ability to inhibit immunoregulatory transcription factor NFkB
in response to a wide variety of carcinogens and inflammatory
agents [27]. However, there are no detailed reports on the
immunosuppressive effects of UA in T cells which are the primary
cell type involved during an adaptive immune response.
To explore the immunomodulatory properties of UA, we
studied its effect on T cell activation, proliferation and effector
responses to different activating stimuli. We observed that UA was
able to inhibit T cell proliferation in response to both polyclonal
and antigen specific activation in a dose dependent manner
Figure 2. Ursolic acid inhibits mitogen induced proliferation of CD4+ T cells, CD8+ T cells and B cell. CFSE labelled purified CD4+T cells
(A) or CD8+Tcells (C) were pre-treated with ursolic acid (5 mM, 4 h) before stimulation with coated anti-CD3mAb (1 mg/ml) and soluble anti CD28mAb
(1 mg/ml) for 72 h at 37uC. Percent daughter cells were calculated from decrease in mean fluorescence intensity. (B&D) Each bar represents
percentage of daughter cells in different treatment groups. (E,F) UA inhibits LPS induced proliferation of B cells. CFSE labeled lymphocytes were
treated with UA (5 mM, 4 h) and stimulated with the LPS (50 mg/ml) at 37uC for 72 h. Vehicle treated cells served as control. Percent daughter cells
were calculated from decrease in mean fluorescence intensity. Each bar represents mean6S.E.M. from three replicates and two such independent
experiments were carried out. *p,0.01, as compared to vehicle treated cells and #p,0.01, as compared to Con A or LPS or anti-CD3/anti-CD28
stimulated cells.
doi:10.1371/journal.pone.0031318.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31318Figure 3. Ursolic acid inhibits cytokine secretion by T cells and macrophages. Lymphocytes were pre-treated with different concentrations
of UA for 4 h before stimulation with Con A (5 mg/ml) (A) or anti-CD3/anti-CD28 mAb (B) for 24 h at 37uC. Vehicle treated cells served as control. The
concentration of cytokines in the culture supernatant was estimated using ELISA. (C) UA inhibits anti-CD3/anti-CD28 induced cytokine secretion by
CD4+T cells. Purified CD4+T cells were pre-treated with different concentrations of UA for 4 h before stimulation with anti-CD3/anti-CD28 mAb for
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increased apoptosis in T cells but due to its ability to induce cell
cycle arrest in G1 phase (Fig. 1E–G). The immunosuppressive
effects of UA were not limited to CD4+ and CD8+ T cells
(Fig. 2A–D), but it also suppressed LPS induced proliferation of B
cells (Fig. 2E&F) suggesting a common mechanism its of action in
these lymphocyte subsets. Cytokines secreted by different cells
participating in the immune response are known to play a critical
role in successful pathogen clearance. Any alteration in this highly
regulated network of cytokines by external or internal factors may
result in undesirable consequences. IL-2, TNF-a, and IFN-c are
secreted by Th1 type cells and can activate macrophages and
promotes cell-mediated immune responses against invasive
intracellular pathogens. Th2 (IL-4, IL-5, IL-6, IL-10, and IL-13)
cytokines promote humoral immune responses against extracellu-
lar pathogens [35]. UA suppressed both Th1 and Th2 cytokines
secreted by activated lymphocytes in response to both polyclonal
and antigen specific stimuli in vitro (Fig. 3A–C). Interestingly, UA
also mitigated LPS induced secretion of IL-1b, TNF-a and IL-6 in
splenic adherent macrophages (Fig. 3D). Quantitative real time
RT-PCR for 6 genes which were known to be involved in
activation and proliferation of T cells was performed and UA also
suppressed the expression of these genes (Fig. 3E). These results
suggested that UA acts on several cell types in exhibiting anti-
inflammatory activity. Recent investigations suggest cellular redox
status may play key role in the regulation of immune responses .
Addition of antioxidants has been shown to modulate T cell
responses as measured in terms of proliferation and cytokine
secretion implicating the importance of ROS in antigen mediated
T cell activation [16]. Our group has also recently shown that
perturbation of cellular redox status can lead to immunosuppres-
sion [33]. Even though UA was observed to increase the basal
ROS levels in lymphocytes, the addition of thiol or non-thiol
antioxidants could not abrogate the suppressive effects of UA on
lymphocyte proliferation and cytokine secretion suggesting a redox
independent mechanism of action in lymphocytes (Fig. 5A–D).
Mechanisic studies of anti-inflammatory effects of UA revealed
that it acts not only by inhibiting early events in T cell activation
but also had potent suppressive effects on the co-stimulatory
molecules. It was observed that lymphocytes treated with UA
failed to upregulate T cell activation markers CD69, CD25 and
CD134 and co-stimulatory marker CD28 upon mitogenic
stimulation (Fig. 4A–D). The role of CD28 as the most important
co-stimulatory receptor is well established. Engagement of the T
cell receptor (TCR) in the absence of CD28 costimulation results
in a long-term hyporesponsive state in T cells called clonal anergy
and represents one mechanism of peripheral tolerance [36]. Also,
the interaction of CD134 with CD134L is known to be involved in
T cell activation and also synergize with CD28-B7 co-stimulatory
pathway to generate an efficient T cell effector responses [37,38].
Experiments showing the inhibitory effects of UA on activation
and co-stimulatory markers on B cells (CD19, CD80 and CD86)
also emphasize its ability to block the co-stimulatory pathway
(Fig. 4E–G). The inhibition of LPS induced MHCII on APCs by
UA may also aid in its potent anti-inflammatory properties by
blocking antigen presentation to T cells (Fig. 4H).
Since many of these lymphocyte activation markers, costimu-
latory molecules and cytokine genes are under NF-kB and AP-1
regulation, experiments were performed to examine the effect of
UA on these transcription factors and MAPKinases. Both ERK
and JNK signaling pathways are vital mediators of a number of
cellular processes including growth, proliferation, and survival of T
cells [39,40]. We observed that UA was able to inhibit mitogen
induced phosphorylation of ERK and JNK and their upstream
kinases, MEK and c-raf (Fig. 6A). Further, we also observed that
UA was able to inhibit mitogen induced increase in nuclear levels
of NF-kB, NF-AT and AP-1 in lymphocytes (Fig. 6B–D).
Shishodia et al, have earlier shown suppression of TNF-a induced
NF-kB by UA in different tumor cell lines [27]. However, this
report shows the effect of UA on mitogen induced NF-kB and its
regulated proteins in normal lymphocytes (Fig. 6. B,E&F). Signal 2
mediated by CD28-B7 interaction is required for the induction of
NF-kB and AP-1 in Ag-stimulated T cells [41] . This CD28
signaling is provided by the costimulatory molecules B7-1/B7-2
present at the cell surface of APCs [42]. The inhibition of NFkB
and AP-1 exhibited by UA might be a consequence of its ability to
block the co-stimulatory pathway by down regulating the levels of
CD28 and B7. For complete T cell activation and cytokine
secretion, the cooperative binding of NF-AT and AP-1 to
composite NF-AT/AP-1 binding sites is necessary [43,44,45].
The inhibition of NF-AT by UA may lead to inhibition of IL-2
secretion and the observed anti-inflammatory effects. Thus, UA
inhibits the activation of the transcription factors NF-AT, NF-kB,
and AP-1 which are required to function in a co-ordinated manner
to regulate antigen induced immune response.
More importantly, we demonstrated the immunosuppressant
activity of UA in vivo. We studied the in vivo anti-inflammatory
potential of UA using a mouse model of graft-versus-host-disease
which is a frequent complication of allogenic bone marrow
transplant in which the engrafted donor T cells attack the
recepients’ organs and tissues. Clinically, cyclosporine A and
tacrolimus have been used in organ transplantation to prevent
allograft rejection [46] . However, these drugs are reported to
show undesirable side effects that needs to be overcome before
they can be used in other inflammatory disorders and autoimmune
disease [20,47]. We observed that treatment of donor lymphocytes
with UA prior to allogenic transplantation significantly improved
symptoms associated with acute GVHD, delayed GVHD
associated mortality and morbidity in recipient mice (Fig. 7A&B)
and also decreased the levels of proinflammatory cytokines in the
serum (Fig. 7C–E). Interestingly, UA was able to inhibit Con A
induced cytokine secretion in murine lymphocytes even when
added up to 4 h post-stimulation (Fig. 7F). Consistent with
previous results, UA treatment induced a state of hypo-
responsiveness in lymphocytes. Further, lymphocytes treated with
UA, washed and rested for 48 h showed decreased secretion of IL-
2 in response to Con A stimulation (Fig. 7G).
24 h at 37uC. The concentration of cytokines in the supernatant was estimated using ELISA. (D) UA inhibits LPS induced cytokine production from
macrophage. Splenic adherent macrophage were pre-treated with UA (5 mM, 4 h) and then stimulated with LPS (50 mg/ml) for 24 or 48 h. The
concentration of cytokines in the supernatant was estimated using ELISA. Each bar represents mean6S.E.M. from three replicates and two such
independent experiments were carried out. *p,0.01, as compared to vehicle treated cells and #p,0.01, as compared to Con A or LPS or anti-CD3/
anti-CD28 stimulated cells. (E) Quantative real time RT-PCR analysis of differential genes expression in CD4+ T cells activated with antiCD3/CD28 in
the presence or absence of Ursolic acid. Purified CD4+T cells were pre-treated with UA for 4 h before stimulation with anti-CD3/anti-CD28 mAb for
24 h at 37uC. The relative expression ratio was calculated and plotted as mean 6 SEM. *p,0.01, as compared to vehicle treated cells and #p,0.01, as
compared to anti-CD3/anti-CD28 stimulated cells.
doi:10.1371/journal.pone.0031318.g003
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31318In a recent report by Liu et al., UA induced tolerance to allogenic
cardiac transplant in mice was attributed to suppression of NF-kB
[48]. They have shown that UA suppressed T cellresponses including
NF-kB inhibition at 25 mM whereas we have observed that a dose of
5 mM was sufficient to suppress immune cell (T cell, B cell and
macrophage) activation. Apart from this, Tao Xu et al., have shown
that anti-inflammatory effects of UA are mediated through
suppression of transcription regulator RORct resulting in decreased
IL-17 expression in Th17 cells [49]. Further, our studies demonstrate
that besides NF-kB suppression UA also suppressed other immuno-
logically important transcription factors AP-1, NF-AT as well as
MAPKinases. In conclusion, the present report identified multiple
cellular targets of ursolic acid and underlines its application as a
potent anti-inflammatory agent with therapeutic potential.
Figure 4. Ursolic acid suppresses inducible expression of T cell and B cell activation markers and co-stimulatory molecules.
Lymphocytes were treated with UA (5 mM, 4 h) and then stimulated with Con A (10 mg/ml) or LPS (50 mg/ml) for 24 h (A–B) or 48 h(C–H) at 37uC. In
each group, 1610
6 cells were stained with PE conjugated anti-CD69 (A) or anti-CD25 (B) or anti-CD134 (C) or anti-CD28 (D) or anti-CD19 (E) or anti-
CD80 (F) or anti-CD86 (G) or anti-I-A (H) mAbs. Representative flowcytometric histogram and corresponding bar diagram are shown. Data points
represent mean6S.E.M. from three replicates and two such independent experiments were carried out. *p,0.01, as compared to vehicle treated cells
and #p,0.01, as compared to Con A or LPS stimulated cells.
doi:10.1371/journal.pone.0031318.g004
Figure 5. Ursolic acid Modulates cellular ROS levels. (A) UA increased ROS levels in lymphocytes. Lymphocytes were stained with DCF-DA
(20 mM, 30 min at 37uC), treated with UA (0.5–5 mM) for 1 h and fluorescence emission was measured at 535 nm. *p,0.01, as compared to DCF
treated cells (B) Effect of UA on intracellular GSH levels. Lymphocytes were treated with UA for 4 h at 37uC and stained with MCB (final concentration
40 mM) for 30 min. Fluorescence emission was measured at 490 nm following excitation at 394 nm. *p,0.01, as compared to MCB treated cells (C)
Immunosuppressive effects of UA were independent of cellular redox status. Lymphocytes were incubated with different antioxidants (GSH or NAC or
DTT or trolox) for 2 h. These cells were then stimulated with Con A in presence or absence of UA for 24 h at 37uC .The concentration of IL-2 and IFN-c
in the culture supernatant was estimated by ELISA. (D&E) Lymphocytes were stained with CFSE and were incubated with different antioxidants (GSH
10 mM or NAC 10 mM or DTT 100 mM or trolox 100 mM) for 2 h. The cells were then stimulated with Con A in presence or absence of UA for 72 h at
37uC. Cell proliferation was measured from CFSE dye dilution using a flowcytometer. Representative flowcytometric histograms and corresponding
bar diagram are shown (Fig. 5D&E). Each bar shows mean6S.E.M from three replicates and two such independent experiments were carried out.
*p,0.01, as compared to vehicle treated cells and #p,0.01, as compared to Con A stimulated cells.
doi:10.1371/journal.pone.0031318.g005
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31318Figure 6. Inhibition of proliferation/survival associated signaling molecules by ursolic acid in activated T cells. Lymphocytes were
incubated with UA (5 mM, 4 h) and stimulated with Con A (5 mg/ml) for 1 h. Whole cell lysates were prepared, fractionated on 10% SDS–PAGE, and
electrotransferred to nitrocellulose membrane. Western blot analysis was performed using different antibodies specific for (A) p-c-Raf, p-MEK, p-ERK,
ERK, p-JNK and JNK (B) IkBa and b-Actin (loading control). (C–E) Lymphocytes were incubated with 5 mM UA for 4 h and then stimulated with Con A
(5 mg/ml) for 1 h. Nuclear extracts were prepared and analysed for NF-kB (B), NF-AT (C) and AP-1 (D) activation by EMSA. (E&F), UA inhibits NF-kB
dependent gene products in activated lymphocytes. Lymphocytes were incubated with UA (5 mM, 4 h) and were stimulated with Con A (5 mg/ml) for
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Chemicals
Ursolic acid, RPMI-1640, HEPES, EDTA, EGTA, PMSF,
leupeptin, aprotinin, benzamidine, dithiothreitol (DTT), glutathi-
one (GSH), N-acetyl cysteine (NAC), NP40, propidium iodide,
lipopolysaccharide (LPS) and dimethyl sulfoxide (DMSO) were
purchased from Sigma Chemical Co. (USA). Fetal calf serum
(FCS) was obtained from GIBCO BRL. Concanavalin A (Con A)
and trolox were purchased from Calbiochem, USA. ELISA sets
for detection of cytokines (IL-2, IL-4, IL-6, IFN-c, TNF-a and IL-
1b) and monoclonal antibodies against Bcl-2, Bcl-xl, CD25,
CD69, CD19, CD80, CD86, MHCII, CD134 and CD28 labeled
with PE were procured from BD Pharmingen (USA). Antibodies
against p-ERK, ERK, IkB-a, p-MEK, p-c-Raf, p-JNK, JNK and
b-actin were obtained from Cell Signaling Technologies (USA).
Approval of animal ethics Committee
‘The Institutional Animal Ethics Committee of Bhabha Atomic
Research Centre, Government of India’, has approved the animal
studies and the guidelines issued by the ethics committee regarding
the maintenance and dissections of small animals were strictly
followed. Project No. BAEC/11/10 and Date of approval: April,
2010.
Treatment with ursolic acid
A 20 mM solution of ursolic acid was prepared in dimethyl
sulfoxide, stored as small aliquots at 220uC and diluted as needed
in cell culture medium. In all in vitro experiments, cells were
treated with different doses of ursolic acid for 4 hours before the
initiation of culture. DMSO (0.1%) was used as vehicle control in
vitro.
Proliferation assay
Splenic lymphocytes were obtained by squeezing the spleen
through a nylon mesh in a petri plate containing RPMI medium.
The RBC were lysed by brief hypotonic shock. Splenic
lymphocytes were stained with CFSE (20 mM, 5 min, 37uC) and
washed three times using ice-cold RPMI medium containing 10%
FCS, 100 IU/ml penicillin and 100 mg/ml streptomycin. Two
million splenic lymphocytes were treated with ursolic acid
(0.25 mMt o5mM, 4 h) and were stimulated with Con A (5 mg/
ml) or LPS (50 mg/ml) for 72 h at 37uC in 2 ml RPMI with 10%
FCS in a 95% air/5% CO2 atmosphere. Vehicle treated cells
served as a control. Cell proliferation was measured by dye
dilution in a flowcytometer (Partec CyFlow). Percent daughter
cells that showed a decrease in CFSE fluorescence intensity were
calculated using FlowmaxH software and were expressed as
daughter cells [50].
CD4+ and CD8+ T cell isolation and proliferation assay
CD4+ (purity: 93%) & CD8+ (purity: 92%) T cells were isolated
by using EasySep immunomagnetic cell sorting kit from Stem Cell
Technologies, with PE labelled anti-CD4 antibody conjugated to
magnetic nanoparticles through dextran and separation using
magnetic field. For cell proliferation analysis, total splenocytes
were first labelled with CFSE and then sorted and cultured for 24
or 72 h respectively for cytokine or proliferation assay.
Estimation of cell cycle and apoptosis
The percentage of cells in different phases of cell cycle (G1,
S+G2/M) and percentage of apoptotic cells was estimated using a
flowcytometer. One million splenic lymphocytes were treated with
ursolic acid (0.25–5 mM) for 4 h and stimulated with Con A for
72 h at 37uC in RPMI1640 medium supplemented with 10% FCS
in a 5% CO2 atmosphere. Vehicle treated cells served as control.
The cells were washed with PBS and incubated with 1 ml of
staining solution containing 0.5 mg/ml propidium iodide, 0.1%
sodium citrate and 0.1% triton X-100 overnight [51]. A total of
20,000 cells were acquired on Partec Cyflow flowcytometer and
analyzed using FloMaxH software. Undivided cells were in G1
phase of cell cycle (2n DNA content). The pre G1 population
represented the apoptotic cells. The population showing more
than 2n DNA represented cells in S+G2/M phase of cell cycle.
Measurement of cytokine secretion
The concentration of IL-2, IL-4, IL-6 and IFN-c in the
supernatant of control unstimulated cells and cells stimulated with
Con A for 24 h after ursolic acid treatment (4 h) was estimated
using cytokine ELISA sets (BD Pharmingen, USA). The
supernatant obtained from Con A stimulated cells was used as
positive control. Cytokines induced by LPS was estimated in the
culture supernatant of splenic adherent macrophage. Spleen cells
(5610
6 cells/well) were incubated in a 24-well cell culture plate for
3 h at 37uC in a humidified atmosphere of 5% CO2 and 95% air.
The non-adherent cells were removed by aspiration. The adherent
cells (macrophages) were incubated with ursolic acid (5 mM for
4 h) and then stimulated with LPS (50 mg/ml) and further cultured
for 6 h or 24 h at 37uC. The concentration of IL-6 and TNF-a in
the supernatant of LPS stimulated cells for 6 h and IL-1b for 24 h
was estimated using cytokine ELISA sets (BD Pharmingen, USA)
[52].
Intracellular ROS measurements: To detect intracellular
ROS, lymphocytes were incubated with 20 mM oxidation-sensitive
dichlorofluorescein diacetate (DCF-DA) for 20 min at 37uC before
being treated with various concentrations of ursolic acid. After 1 h
of incubation, the increase in fluorescence resulting from oxidation
of H2DCF to DCF was measured using a spectrofluorimeter [53].
Intracellular GSH assay
To measure intracellular GSH, lymphocytes were treated with
ursolic acid for 4 h at 37uC. Monochlorobimane (final concentra-
tion, 40 mM, 30 min 37uC) was loaded into cells. Fluorescence
emission from cellular sulfhydryl-reacted monochlorobimane was
measured using a spectrofluorimeter (BMG Labtech Optima).
Monochlorobimane is also known to react with small-molecular-
weight thiols other than GSH but GSH forms the major
monochlorobimane reactive thiol. Hence, MCB fluorescence is
referred to as GSH levels in this manuscript. There are several
reports in the literature measuring GSH levels using this dye.
Intracellular and surface antibody staining
Three million lymphocytes cells were cultured in presence or
absence of ursolic acid for 4 h and then stimulated with Con A for
24 h at 37uC. Cultured cells were fixed with 4% paraformalde-
hyde for 10 min at room temp and excess of paraformaldehyde
was removed by washing once with wash buffer (PBS containing
24 h, harvested, fixed, permeablized and stained with PE labelled Bcl-2 antibody or Bcl-xl antibody. Representative flowcytometric histograms (E) and
the corresponding bar diagram (F) are shown. Each bar shows mean6S.E.M from three replicates and two such independent experiments were
carried out. *p,0.01, as compared to vehicle treated cells and #p,0.01, as compared to Con A stimulated cells.
doi:10.1371/journal.pone.0031318.g006
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and Bcl-xl, cells were permeabilized with PBST (PBS cotain-
ing0.02% tween-20) thrice for 5 min each at room temperature
followed by 2 washes with wash buffer and then incubated with the
indicated antibodies for 30 min at room temperature, washed
twice and analyzed using a Partec Cyflow flowcytometer.
Surface staining with PE labeled antibodies was done as
described earlier [52]. In brief, splenic lymphocytes were treated
with ursolic acid (5 mM, 4 h) and were further stimulated with Con
A (10 mg/ml) or LPS (50 mg/ml) for 24 h or 48 h. Staining with
PE conjugated CD25 antibody or CD69 antibody were done with
cells (1610
6) obtained after 24 h treatment, while those with
CD28, CD134, CD19, CD80, CD86, MHCII were done with
cells (1610
6) obtained after 48 h treatment. A total 20,000 cells in
each group were acquired and analyzed in a Partec Cyflow
flowcytometer.
Western blot analysis
Splenic lymphocytes were treated with ursolic acid (5 mM, 4 h)
and were stimulated with Con A (5 mg/ml) for 1 h at 37uC and
cytosolic extract or whole cell extract was prepared as described
earlier [54] . Vehicle treated cells served as control. Briefly, cells
were washed with ice-cold phosphate buffered saline and
suspended in 0.1 ml lysis buffer (10 mM HEPES, pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothre-
itol, 0.5 mM PMSF, 2 mg/ml leupeptin, 2 mg/ml aprotinin, and
0.5 mg/ml benzamidine). Then cells were allowed to swell on ice
for 15 min, after which 25 ml of 10% NP-40 was added and tubes
were vortexed. The supernatants containing proteins from
cytosolic fraction were collected by centrifuging the cells at
8000 rpm for 6 min at 4uC. The pellet were suspended in nuclear
extraction buffer for performing EMSA as described below.
Protein estimation was carried out by Bradford method using Bio-
Rad Protein Assay Kit. Equal amounts of protein (50 mg) were
resolved by SDS-PAGE (10%) and transferred to nitro cellulose
membrane. After the membrane was blocked in 5% nonfat
powdered milk, it was incubated overnight with the primary
antibody specific to IkB-a or p-c-Raf or p-MEK or p-ERK or p-
JNK and washed three times with Tris-buffer saline containing
0.05% tween 20 (TBST) and further incubated with horseradish
peroxidase-labeled secondary antibody for 1 h. The membranes
were washed, and specific bands were visualized on X-ray films
using enhanced chemiluminiscence kit (Roche, Germany). The
membrane was stripped and reprobed with actin-b or ERK or
JNK antibody.
Electrophoretic mobility shift assay
Splenic lymphocytes were treated with ursolic acid (5 mM, 4 h)
and were stimulated with Con A (5 mg/ml) for 1 h at 37uC and
nuclear extracts were prepared. The nuclear pellets were
resuspended in 25 ml of ice cold nuclear extraction buffer
(20 mMHEPES, pH 7.9, 0.4MNaCl, 1 mM EDTA,
1 mMEGTA, 1 mMDTT, 1 mMPMSF, 2.0 pg/ml leupeptin,
2.0 mg/ml aprotinin, and 0.5 mg/ml benzamidine), and the tubes
were incubated on ice for 60 min with intermittent agitation.
Samples were microcentrifuged for 5 min at 12,000 rpm, and the
supernatant was collected in fresh tubes and frozen at 270uC.
EMSA was performed by incubating 10 mg of nuclear proteins
with 16 fmol of 32 P-end-labeled, double stranded NF-kB
oligonucleotides from the human immunodeficiency virus long
terminal repeat (59-TTGTTACAAGGGACTTTCCGCTGGG-
GACTTTCCAGGGAGGCGTGG-39; boldface indicates NF-kB
binding sites) or AP-1(59-CGCTTGATGACTCAGCCGGAA-39;
boldface indicates AP-1 binding site) or NF-AT(59-CGC CCA
AAG AGG AAA ATT TGT TTC ATA-39; boldface indicates
NF-AT binding site) in the presence of 0.5 mg of poly (29-
deoxyinosinic-29-deoxycytidylic acid) (poly (dI–dC)) in binding
buffer (25 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.5 mM
dithiothreitol,1% NP 40, 5% glycerol, and 50 mMNaCl) for
30 min at 37uC. The DNA–protein complex formed was
separated from free oligonucleotide on 6.6% native polyacryl-
amide gels using buffer containing 50 mM Tris, 200 mM glycine,
and 1 mM EDTA, pH8.5. The dried gel was exposed on
phosphorimage plate and the radioactive bands were visualized
Figure 7. In vivo immunosuppressive effect of Ursolic acid. (A, B) Ursolic acid delayed mortality and weight loss in GVHD mice: Eight million
lymphocytes from C57BL/6 donor mice were injected i.v. into immunocompromised Balb/c mice 48 h after WBI (600 cGy). Ten mice were included in
each group. Control group mice received vehicle treated cells whereas the UA group received cells treated with 5 mM UA for 4 h. (A) Survival of the
immunocompromised mice reconstituted with allogenic lymphocytes treated with UA or vehicle. *p,0.05, as compared to mice injected with vehicle
treated allogenic lymphocytes. (B) Changes in the body weight of the mice after allo-transplantation. Data points represent mean6SEM from 10 mice.
Changes in levels of IL-2 (C), IL-6 (D) and IFN-c (E) in serum separated from the blood collected on days 3 and 5 from recipient mice (Balb/c) injected
with vehicle treated lymphocytes or UA treated lymphocytes isolated from C57BL/6 mice (F) Ursolic acid inhibits cytokine production in activated
lymphocytes. Lymphocytes were stimulated with Con A (5 mg/ml) following which UA (5 mM) was added at the indicated time points and the cells
were further cultured for 24 h at 37uC. The concentration of IL-2 cytokines in the culture supernatant was estimated using ELISA. (G) Ursolic acid
inhibits Con A induced cytokine production even after washing. Lymphocytes were treated with UA (5 mM)) for 4 h and washed with normal RPMI
twice, rested for 48 h and then stimulated with Con A (5 mg/ml) for 24 h at 37uC. The concentration of IL-2 in the culture supernatant was estimated
using ELISA. Each bar represents mean6S.E.M. from three replicates and two such independent experiments were carried out. *p,0.01, as compared
to vehicle treated cells and #p,0.01, as compared to Con A stimulated cells.
doi:10.1371/journal.pone.0031318.g007
Table 1. List of primer sequences used for real time
quantitative PCR.
Gene Sequence
Cdc25a Forward: ACAGCAGTCTACAGAGAATGGG
Reverse: GATGAGGTGAAAGGTGTCTTGG
E2F Forward: CAGAACCTATGGCTAGGGAGT
Reverse: GATCCAGCCTCCGTTTCACC
Gadd45g Forward: GGGAAAGCACTGCACGAACT
Reverse: AGCACGCAAAAGGTCACATTG
Plcg2 Forward: GTGGACACCCTTCCAGAATATG
Reverse: ACCTGCCGAGTCTCCATGAT
Mcm7 Forward: AGTATGGGACCCAGTTGGTTC
Reverse: GCATTCTCGCAAATTGAGTCG
IFN-gamma Forward: TGGAGGAACTGGCAAAAGGATGGT
Reverse: TTGGGACAATCTCTTCCCCAC
IL-2 Forward: TGATGGACCTACAGGAGCTCCTGAG
Reverse: GAGTCAAATCCAGAACATGCCGCAG
b-actin Forward: GCGGGAAATCGTGCGTGACATT
Reverse: GATGGAGTTGAAGGTAGTTTCGTG
doi:10.1371/journal.pone.0031318.t001
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USA).
Induction of Graft-Versus-Host Disease (GVHD)
Balb/c mice were exposed to 600 cGy whole body gamma-
radiation (WBI) (Gamma Cell 220, AECL Canada). To induce
GVHD in immunocompromised Balb/c mice, 8610
6 splenic
lymphocytes from C57BL/6 donors were injected i.v. 48 h after
irradiation. Each mice in control group received vehicle treated
splenic lymphocytes, whereas each mice in the ursolic acid group
received splenic lymphocytes treated with 5 mM ursolic acid for
4 h. The recipient mice were monitored daily to assess the signs of
GVHD. A total of 10 mice were used per group. GVHD became
evident from rapid and sustained weight loss as well as from
features such as hunchback, diarrhoea, hair loss and death. Serum
was separated from the blood collected on days 3 and 5 from
recipient mice (Balb/c) injected with vehicle treated lymphocytes
or UA treated lymphocytes taken from C57BL/6 mice and levels
of different cytokines were estimated using sandwich ELISA.
Quantitative real-time RT-PCR
mRNA levels in the samples were quantified by quantitative
real-time RT-PCR as described previously [55]. Briefly, total
RNA was isolated from the samples using Trizol reagent following
the manufacturer’s instructions (Sigma) and was dissolved in
deionised DEPC-treated water. From this RNA 2 mg was
converted to cDNA by reverse transcription (cDNA synthesis kit)
following the manufacturer’s instruction (sigma). qPCR was
carried out using the Rotor Gene 3000 (Corbett Research)
machine. The PCR was setup by mixing 106SYBR green PCR
mix (sigma) with 5 ml cDNA, 10 picomoles each of forward and
reverse primers (Table 1), and PCR-grade water in 20 ml reaction
system. The above reaction mixtures were amplified in the
following steps: step 1-denaturation at 95uC for 5 min; step 2-
denaturation at 95uC for 15 s; step 3-annealing at 57uC for 15 s;
step 4-extension at 72uC for 20 s; step 5-melting curve analysis.
Steps from 2 to 4 were repeated for 40 cycles. The specificity of
respective amplicons was confirmed from the melting curve
analysis. The amplification of each gene was carried out in
triplicates for each group. The threshold cycle (the cycle at which
the amplification enters into exponential phase) values obtained
from above runs were used for calculating the expression levels of
genes by REST-384 version 2 software [56]. The expressions of
genes were normalized against that of a housekeeping gene, b-
actin, and plotted as relative change in the expression with respect
to control.
Statistical analysis
Data are presented as mean 6 SEM. The statistical analysis was
done using ANOVA with Microcal Origin 6.0 software followed
by post-hoc analysis using Schiffe’s test. *refers to p,0.01, as
compared to vehicle treated control and # refers to p,0.01, as
compared to Con A or LPS stimulated cells. Log rank test was
used to compare GVHD related mortality in mice injected with
control or UA treated allogenic lymphocytes.
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